DOCSLIB.ORG

A C10mparative Clinical Trial on Bantu Psychotic Patients *

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A C10mparative Clinical Trial on Bantu Psychotic Patients * 28 August 1971 S.A. MEDICAL JOURNAL 945 As yet there is no generally accepted table for com­ 5. South African Bureau of Standards (1970): SABS Publication 083­ 1970. Pretoria: GOVl Printer. pensation purposes' based, for example on the percentage of 6. Organization for Health Research (T 0) (1963): Geluidspectra hearing impairment and resultant disability, which might 'T1 rt.fdelingSaudiOgrammen in de Nederlandse Indus/rie. The Hague: be calculated by the abovementioned method and related 7. Glorig, A., DLxon Ward, W. and Nixon, l. (1961): Arch. Otolaryng. 74, 413. (Copyright 1961, American Medical Association.) to the wage a worker was earning at the time of examina­ 8. Bell, A. (1966): W.H:O. Public Health Paper 30. Geneva: WHO. 9. Bums, W. and Robmson, D. W. (1970): Hearing and Noise in tion for considering his claim. Although this may be re­ Industry. London: HMSO. garded as desirable, it is not a medical problem and may 10. Organization for Health Research (TNO) (1962): Recommendations for Noise Measurement in the Industry. The Hague: TNO. be left to the appropriate authority in each country. 11. Glorig, A. (1961): 1. Laryng., 75, 447. 12. Laevens, J. (1969): T. soc. Geneesk., 47, 194. 13. American Industrial Hygiene Association (1966): Industrial Noise Manual. Southfield, Mich.: AlliA. I should like to thank Mr G. V. Meij of the South African 14. Lindeman, H. E. and Van Leeuwen, P. (1967): T. soc. Geneesk., 45, Bureau of Standards, Pretoria, for checking the manuscript. 814. 15. National Safety Council (1967): Fundamentals of Industrial H}giene. Chicago: NatIonal Safety Council. 16. Report of the Intersociety Committee (1967): Amer. Industr. Hyg. REFERENCES Assoc. 1., 28, 418. 17. Meij. G. V. (1968): The Certificated Engineer, p. 272. I. S.A. National Council for the Deaf (1962): Report on the Second 18. Mel), G. V., Hendrikse, W. J. and Breed, J. A.: Standardized Loudness National Conference on Noise. Balance Method of Determining Auenuacion of Ear-Protectors. Pretoria: 2. Van der Sandt, W. (1970): S. Afr. Med. l., 44, 558. SABS. 3. International Wrought Copper Council, London (1968): Imroduction 19. Committee on Medical Rating of Physical Impairment AMA (1961): to the Srudy of Noise in Industry. Surrey, UK: Unwin. 1. AIDer. Med. Assoc., 177, 489. (Copyright 1961, American Medical 4. American Academy of Ophthalmology and Otolaryngology (1969): Association.) Guide for Conservation of Hearing in Noise. Rochester. Minn.: AAOO. 20. Heron, T. G. (1968): S. Afr. Med. l., 42, 558. Chlorpromazine, Clotiapine and Thioridazine- A C10mparative Clinical Trial on Bantu Psychotic Patients * A. J. VAN WYK, Professor of Psychiatry, University of Pretoria, AND G. F. T. MARAIS, Psychiatric Clinical Assistant, Weskoppies Hospital, Pretoria SUMMARY No side-effects were seen with thioridazine and extra­ pyramidal side-effects caused by the other two drugs In a non-blind assessment of 3 neuroleptic drugs, chlor­ were easily controlled by dose reduction. promazine (Largactil), thioridazine (Melleril) and c1otia­ pine (Etomine), we found Etomine to be the drug of S. Air. Med. J., 45, 945 (1971). choice when the diagnosis is in doubt between a toxic psychosis or schizophrenia. This drug also offered the Early in 1968, the drug clotiapine (Etomine, Wander) highest discharge rate, 77'7% at 12 weeks compared with became available in South Africa for clinical trials. At that 73'5% in the thioridazine group, and 55'5% in the chlor­ stage the available literature'" indicated that because of its promazine group. quick action, it might be useful in increasing patient turn­ over rate, especially in the Bantu wards where we have a No clouding of consciousness was seen in the clotia­ high admission rate. pine group, whereas it was troublesome in the chlorpro­ mazine group in patients having received high parenteral It was decided to launch a clinical investigation, com­ doses. paring its effects with chlorpromazine and thioridazine, two well-known and often used neuroleptics in the Bantu 'Date received: 26 April 1971. wards. 14 946 S.-A. MEDIESE TYDSKRIF 28 Augustus 1971 METHOD remained symptom free for the following 4 weeks, were they discharged. No patients were discharged on medica­ Because of the administrative and staff shortage problems tion but a letter to the district surgeon stating the treat­ we could not introduce any 'blind' procedures into the ment which had been received, was given to all discharged trial. However, we hoped that by using a fair number of to be handed in to their district surgeon on arrival home. patients and following them through until discharge, we might nevertheless be able to gather enough data for a global evaluation of the 3 drugs. RESULTS All patients were physically healthy adult Bantu males suffering from acute psychoses. No epileptic or depressive Figs. 1 and 2 show the differences in action m the two psychoses were included and on subsequent analysis it main diagnostic categories. was found needful to divide all patients into two broad diagnostic groups, e.g. schizophrenia and toxic psychosis (Table I). ..•...... ;,.;;;./................. TABLE I. NUMBER OF PATIENTS y ••••.•. : -~ . -/ --"" :-~""":: . Treatment Schizophrenia Toxic Total ,//~-------~ psychosis -- Clotiapine c,c' (Etomine) 28 8 36 .:,c, Thioridazine .:, 21. // (Melleril) 21 10 31 :15':/ Chlorpromazine IoII1US >< >< CRLORP1IOMAZUIB (Largactil) 25 9 34 x_>< CLOTHI&PINIl " ••• " THIORIDJ,ZUIII Allocation to either of the 3 drug groups was at random Fig. 1. Results in schizophrenia. and all patients were handled by the same staff and the same clinical investigator throughout the trial. Diagnoses were confirmed before final diagnostic grouping. --?/:::::.~_=-__=__::::.__=-=-_=__...=-::= ..2 Psychosis ratings were done before treatment and there­ after weekly for 12 weeks or until discharge. The psychosis rating scale was a very simplified tabulation of the usual ...-""'" important psychiatric signs and symptoms with which .r········- - . Bantu patients present. All patients were scored from 1 ......... " (normal) through 5 (severely disordered) on 5 diagnostic criteria, e.g. orientation~ insight, delusions, hallucinations and general behaviour. .•.... No patients received concurrent electroconvulsive or ........ antiparkinsonism therapy during the trial. 10 ..... I."llJIU x--x CHLORPllOIUZINB ]1_]1 CLOTIfIAPUI. Dosage ", •.• x TIiIOll.ID£ZI!I!" Toxic All patients received an initial maximum recommended Fig. 2. Results in toxic psychosis. dose of each drug. Dosage was reduced when improve­ ment or side-effects began to occur. Ootiapine: 40 mg t.d.s. oraUy. Because of restlessness It is interesting to note, in the schizophrenic group, a and agitation in 11 patients the initial treatment was definite lag in the chlorpromazine curve below the other limited to a single dose on the first day (120 mg), given two drugs. Also in the toxic group there is a definite lag intravenously, to be followed only on the second day with in the thioridazine curve below the other two drugs. the normal daily dosage orally. When calculating a discharge rate after 12 weeks treat­ Chlorpromazine: 200 mg t.d.s. oraUy. Due to agitation ment we obtained the results shown in Table n. and restlessness, 4 patients received an initial dose of 100 mg intramuscularly, followed after 8 hours and 16 hours with oral medication, to make up the total daily dosage of TABLE 11. PERCENTAGE PATIENTS DISCHARGED 600 mg. Thioridazine: 200 mg t.d.s. oraUy. 10 patients received Toxic Total 300 mg t.d.s. on the first day to alleviate agitatiQn and Treatment psychosis Schizophrenia discharged restlessness. Chlorpromazine 26'1% 29'4% 55'5% Medication was discontinued when patients rated 'symp­ Clotiapine 16'7% 61'0% 77-7% tom free' for 2 consecutive weeks, and only when they Thioridazine ' 21'2% 52'3% 73'5% 28 August 1971 S.A. MEDICAL JOURNAL 947 DISCUSSION that clothiapine (Etomine, Wander) gives rapid response in both schizophrenia and toxic psychoses. By using either of The total rating of all symptoms before beginning treat­ the other two drugs at the time when exact diagnosis is ment (x) was computed for each patient. In addition, their still in doubt, one might find an unsatisfactory response. total rating of all symptoms after 1, 2 and more weeks of Furthermore, an advantage of clotiapine over the observation in hospital was determined. (yi, i = 1, 2, ....). other two drugs is the availability of a safe parenteral To obtain the measure of improvement under drug therapy solution. In none of the 11 patients treated with 120 mg (x - iy).lOO clotiapine intravenously did we notice untoward clinical we computed the rate Zi = . In the graphs side-effects either locally or systemically. They all promptly x ~ 5 calmed down and were put to bed. are represented the mean values of Zi computed from all We did notice an upsetting degree of mental clouding patients observed in week 1. The differences between mean in all 4 patients 24 hours after the intramuscular chlor­ values Zi of the 3 drug groups were then tested by Student's promazine injection. It was so severe that it was only I-test. The small numbers at the beginning and at the with difficulty that any information could be obtained from end of the curves represent the number of patients from them the next day. which the mean was computed. This clouding of consciousness was not present at all in This method has the disadvantage that patients who are patients that had received clothiapine intravenously the cured and discharged from hospital fall out of the cal­ previous day. Although they were heavily sedated, they culation. Their ratings after discharge are not known, and could give a good account and assessment of psychosis it would be wrong to assess them with the minimal rating was therefore much easier with them. for all following weeks. So those discharged early have No extrapyramidal side-effects were noticed in the a negative influence upon the improvement-curves.
Load more

Recommended publications
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • Antipsychotics
    Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder and depression. This factsheet explains more about antipsychotic medication. There are two types of antipsychotics – ‘first generation’ or ‘typical’ (older medications) and ‘second generation’ or ‘atypical’ (newer medications). Antipsychotics affect people differently. If you take antipsychotics then you may get side effects. It can take some time to find the right medication. If you are taking an antipsychotic which you feel is not working, or if the side effects are difficult to live with, then you should discuss this with your GP or psychiatrist. You should not stop taking antipsychotics suddenly. Your antipsychotics can interact with other medications. It is important that your doctor is aware of all the medicine you are taking. This factsheet covers: 1. What are antipsychotics? 2. Are there different types of antipsychotics? 3. Are there any side effects? 4. What if I want to stop taking antipsychotics? 5. Do antipsychotics affect other medication? 6. Does alcohol affect my antipsychotics? 7. Can I drive when taking antipsychotics? 8. What else should I consider before taking antipsychotics? Top 1. What are antipsychotics? Psychosis is a medical term. If you have psychosis, you might see or hear things (hallucinations), or have ideas or beliefs that are not shared by other people around you (delusions). Some people describe it as a ‘break from reality’. Doctors may also describe it as ‘psychotic symptoms’, a ‘psychotic episode’ or a ‘psychotic experience’.
    [Show full text]
  • Dottorato Di Ricerca the Effect of Finasteride
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UniCA Eprints Università degli Studi di Cagliari DOTTORATO DI RICERCA Scuola di Dottorato in Neuroscienze e Scienze Morfologiche Corso di Dottorato in Neuroscienze Ciclo XXIII THE EFFECT OF FINASTERIDE IN TOURETTE SYNDROME: RESULTS OF A CLINICAL TRIAL Settore scientifico disciplinari di afferenza BIO/14 Presentata da: Silvia Paba Coordinatore Dottorato Prof.ssa Alessandra Concas Tutor Dott.ssa Paola Devoto Esame finale anno accademico 2009 - 2010 1. INTRODUCTION 1 1.1 General characteristics of steroid 5α-reductase 2 1.2 S5αR inhibitors 15 1.3 S5αR inhibitors as putative therapeutic agents for some neuropsychiatric disorders. 23 2. AIMS OF THE STUDY 37 3. METHODS 38 3.1 Subjects 38 3.2 Procedures 39 3.3 Data analysis 40 4. RESULTS 41 4.1 Description of sample 41 4.2 Dosing, range and compliance 41 4.3 Effects of finasteride on TS and tic severity 44 4.4 Effects of finasteride on obsessive compulsive symptoms 46 4.5 Adverse effects 47 5. DISCUSSION 48 6. CONCLUSION 52 REFERENCES 54 1. INTRODUCTION The enzyme steroid 5α reductase (S5αR) catalyzes the conversion of Δ4-3-ketosteroid precursors - such as testosterone, progesterone and androstenedione - into their 5α- reduced metabolites. Although the current nomenclature assigns five enzymes to the S5αR family, only the types 1 and 2 appear to play an important role in steroidogenesis, mediating an overlapping set of reactions, albeit with distinct chemical characteristics and anatomical distribution. The discovery that the 5α-reduced metabolite of testosterone, 5α-dihydrotestosterone (DHT), is the most potent androgen and stimulates prostatic growth led to the development of S5αR inhibitors with high efficacy and tolerability.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • South African National Essential Medicine List Primary Level and Adult Hospital Level Medication Review Process Component: Mental Healthcare Conditions
    South African National Essential Medicine List Primary Level and Adult Hospital Level Medication Review Process Component: Mental Healthcare conditions 1. Executive Summary Date: 6 June 2017 Medicine (INN): Clotiapine injection Medicine (ATC): N05AH06 Indication (ICD10 code): Acute aggressive disruptive behaviour (R45.1/4/5/6/F60.3) Patient population: Adults Level of Care: Primary and secondary level Prescriber Level: Medical doctor NNT: n/a Current standard of Care: Chlorpromazine injection / Haloperidol+Promethazine Motivator/reviewer name(s): Dr Lesley Robertson PTC affiliation: Gauteng Provincial PTC 2. Name of author(s)/motivator(s) Dr Lesley Robertson 3. Author affiliation and conflict of interest details Affiliation: University of Witwatersrand; Affiliated to South African Society of Psychiatrists; Committee member of the Adult Hospital Level Expert Review Committee (2017‐2019); Co‐opted to support the Primary Health Expert Review Committee (2016‐2018). Conflicts of interest: Dr Reddy Laboratories annual sponsorship of Public Sector Psychiatry Forum (SASOP); Honararium from Sanofi Aventis (2015) channelled to South African Society of Mental Health and Deafness via SASOP. 4. Introduction/Background As chlorpromazine injection has not been available on contract since 2014 (erratic availability of chlorpromazine from sole supplier) there is a need for an alternative to Haloperidol+Promethazine in the acute management of aggressive and disruptive patients at PHC and hospital level (Adult). (The current Adult Hospital Level STGs and EML, 2015 edition, recommends chlorpromazine injection when haloperidol injection is not available). 5. Purpose/Objective ‐ P: Adults with acute aggressive and disruptive behaviour ‐ I: Chlorpromazine injection ‐ C: Clotiapine injection ‐ O: Rapid tranquilisation, stabilisation 6. Methods Search strategy: The Tripdatabase was searched, using the following search strategy "chlorpromazine AND clotiapine" and articles were restricted to systematic reviews and controlled trials.
    [Show full text]
  • Gianluca BW.Indd
    Use and safety of psychotropic drugs in elderly patients Gianluca Trifi rò GGianlucaianluca BBW.inddW.indd 1 225-May-095-May-09 111:22:461:22:46 AAMM Th e work presented in this thesis was conducted both at the Department of Medical Informatics of the Erasmus Medical Center, Rotterdam, Th e Netherlands and the Depart- ment of Clinical and Experimental Medicine and Pharmacology of University of Messina, Messina, Italy. Th e studies reported in chapter 2.2 and 4.3 were respectively supported by grants from the Italian Drug Agency and Pfi zer. Th e contributions of the general practitioners participating in the IPCI, Health Search/ Th ales, and Arianna databases are greatly acknowledged. Financial support for printing and distribution of this thesis was kindly provided by IPCI, SIMG/Health Search, Eli Lilly Nederland BV, Boehringer-Ingelheim B.V., Novartis Pharma B.V. and University of Messina. Cover design by Emanuela Punzo, Antonio Franco e Gianluca Trifi rò. Th e background photo in the cover is a landscape from Santa Lucia del Mela (Sicily) and was kindly pro- vided by Franco Trifi rò. Th e photo of the elderly person is from Antonio Franco Trifi rò. Layout and print by Optima Grafi sche Communicatie, Rotterdam, Th e Netherlands. GGianlucaianluca BBW.inddW.indd 2 225-May-095-May-09 111:22:481:22:48 AAMM Use and Safety of Psychotropic Drugs in Elderly Patients Gebruik en veiligheid van psychotropische medicaties in de oudere patienten Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • The Effect of the Process Variables on the HPLC Separation of Tricyclic Neuroleptics on a Calixarene-Bonded Stationary Phase
    ORIGINAL ARTICLES Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany The effect of the process variables on the HPLC separation of tricyclic neuroleptics on a calixarene-bonded stationary phase H. Hashem, Th. Jira Received March 15, 2004, accepted May 25, 2004 Priv.-Doz. Dr. Thomas Jira, Ernst-Moritz-Arndt-University Greifswald, Institute of Pharmacy, Pharmaceu- tical/Medicinal Chemistry, F.-L.-Jahnstr. 17, D-17487 Greifswald, Germany [email protected] Pharmazie 60: 186–192 (2005) The chromatographic behavior of a new HPLC-stationary phase with supramolecular selectors on the basis of calixarenes is described for the separation of nine tricyclic neuroleptics. The effects of differ- ent chromatographic conditions (buffer system, pH-value, type and content of organic modifier, injec- tion volume) on the separation of the analytes were studied. Additionally, the effect of structural differ- ences of the neuroleptic analytes was studied. The chemical structure and pKa of the neuroleptics highly influenced their separation on the calix[8]arene phase. The separation of all analytes on the investigated calixarene-bonded stationary phase was possible with a mobile phase of acetonitrile with 30 mM ammonium acetate buffer (pH 3.5) 30 : 70(v/v) using 1 ml/min flow rate. 1. Introduction Neuroleptics which are widely used for the treatment of CH3 psychological problems are basic compounds, mainly thiox- CH3 anthene and phenothiazine derivatives. Many papers de- N N CH3 scribe the separation of this pharmacological group of ana- N N CH3 lytes on the usual RP-stationary phases (Goldstein and Van S CH3 S O Vunakis 1981; Kountourellis and Markopoulou 1991; Trac- CH3 qui et al.
    [Show full text]
  • Trends in the Use of Antipsychotics in the Israeli Inpatient Population, 2004–2013 Alexander M
    Ponizovsky et al. Israel Journal of Health Policy Research (2016) 5:16 DOI 10.1186/s13584-016-0074-7 RESEARCH Open Access Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013 Alexander M. Ponizovsky1,4*, Eli Marom2, Michal Ben-Laish2, Igor Barash1, Abraham Weizman3 and Eyal Schwartzberg2 Abstract Background: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of typical and atypical antipsychotic drugs in the Israeli inpatient psychiatric population throughout the last decade. Methods: Data regarding allocation of typical and atypical antipsychotics, over the period 2004 to 2013, were extracted from the electronic records of SAREL, Israel’s largest private supplier of drugs to healthcare and medical facilities. The data were converted to defined daily doses (DDD) per 1000 inpatients per day. Results: Usage of the ten atypical antipsychotic agents allocated through Israel’s national health care system increased by 73 %, from 128.09 DDD/1000 inpatients/day in 2004 to 221.69 DDD/1000 inpatients/day in 2013. This rise from 2004 to 2013 was largely due to a 1.6-fold increase in the administration of olanzapine (48.31 to 79.57 DDD/1000 inpatients/day), a 4.4-fold increase of quetiapine (9.74 to 43.04 DDD/1000 inpatients/day) and 3.7-fold increase of amisulpride (5.54 to 20.38 DDD/1000 inpatients/day). At the same period, the total utilization of 12 main typical antipsychotics decreased by 15.5 %, from 148.67 DDD/1000 inpatients/day in 2004 to 125.57 DDD/1000 inpatients/day in 2013.
    [Show full text]